脂蛋白(a)与冠心病相关性的研究进展  

Research progress of lipoprotein(a) and coronary heart disease

作　　者：王怡雯 韩拓 王丽霞 李盈 张婷[1] 王聪霞[1] WANG Yiwen;HAN Tuo;WANG Lixia;LI Ying;ZHANG Ting;WANG Congxia(Department of Cardiology,the Second Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710004,China)

机构地区：[1]西安交通大学第二附属医院心血管内科,西安710004

出　　处：《临床心血管病杂志》2022年第11期860-863,共4页Journal of Clinical Cardiology

基　　金：国家自然科学基金面上项目(No:81273878)。

摘　　要：冠心病是严重危害国民生命健康的重要疾病杀手,血脂代谢紊乱是冠心病的主要危险因素。脂蛋白(a)升高在冠心病患者中非常普遍,是他汀降脂治疗达标后心血管高残余风险的重要原因。目前临床广泛使用的降脂类药物,对降低脂蛋白(a)效果十分有限,甚至反而增加脂蛋白(a)水平。传统烟酸类药物的推陈出新与前蛋白转化酶枯草溶菌素9型(PCSK9)抑制剂的问世,为靶向调节脂蛋白(a),改善冠心病患者预后提供新的治疗手段。Coronary heart disease(CHD)is the leading killer that severely damage people’s lives and health,with dyslipidemia as the main risk factor.Elevated lipoprotein(a)is fairly common in patients with CHD,which is an important reason for those with high residual cardiovascular risk after reaching the standard of statins lipid-lowering therapy.Currently,lipid-lowering medications widely used in clinical practice exert limited effect on reducing lipoprotein(a),and even increase its level.The niacin and proprotein convertase subtilisin/kexin type 9(PCSK9)inhibitor provide new therapeutic strategies for targeting lipoprotein(a)to improve the prognosis of patients with CHD.

关 键 词：冠心病 脂蛋白(a) 前蛋白转化酶枯草溶菌素9型 

分 类 号：R541.4[医药卫生—心血管疾病]